262 related articles for article (PubMed ID: 25245263)
1. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy.
Zhan X; Jia L; Niu Y; Qi H; Chen X; Zhang Q; Zhang J; Wang Y; Dong L; Wang C
Biomaterials; 2014 Dec; 35(38):10046-57. PubMed ID: 25245263
[TBL] [Abstract][Full Text] [Related]
2. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment.
Wang Y; Lin YX; Qiao SL; An HW; Ma Y; Qiao ZY; Rajapaksha RP; Wang H
Biomaterials; 2017 Jan; 112():153-163. PubMed ID: 27768970
[TBL] [Abstract][Full Text] [Related]
3. A tumour microenvironment-responsive polymeric complex for targeted depletion of tumour-associated macrophages (TAMs).
Wang Y; Guo G; Feng Y; Long H; Ma DL; Leung CH; Dong L; Wang C
J Mater Chem B; 2017 Sep; 5(35):7307-7318. PubMed ID: 32264180
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
[TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery of Zoledronate to Tumor-Associated Macrophages for Cancer Immunotherapy.
Zang X; Zhang X; Hu H; Qiao M; Zhao X; Deng Y; Chen D
Mol Pharm; 2019 May; 16(5):2249-2258. PubMed ID: 30969779
[TBL] [Abstract][Full Text] [Related]
6. Molecular Repolarisation of Tumour-Associated Macrophages.
van Dalen FJ; van Stevendaal MHME; Fennemann FL; Verdoes M; Ilina O
Molecules; 2018 Dec; 24(1):. PubMed ID: 30577495
[TBL] [Abstract][Full Text] [Related]
7. IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma.
Tan HY; Wang N; Tsao SW; Che CM; Yuen MF; Feng Y
Oncotarget; 2016 Jul; 7(28):43792-43804. PubMed ID: 27270308
[TBL] [Abstract][Full Text] [Related]
8. Using macrophage activation to augment immunotherapy of established tumours.
Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM
Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor associated macrophages (TAMs) via nanocarriers.
Singh Y; Pawar VK; Meher JG; Raval K; Kumar A; Shrivastava R; Bhadauria S; Chourasia MK
J Control Release; 2017 May; 254():92-106. PubMed ID: 28377038
[TBL] [Abstract][Full Text] [Related]
10. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
Wang Y; Luan Z; Zhao C; Bai C; Yang K
Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
[TBL] [Abstract][Full Text] [Related]
11. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
Ngambenjawong C; Gustafson HH; Pun SH
Adv Drug Deliv Rev; 2017 May; 114():206-221. PubMed ID: 28449873
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection.
Huang Z; Gan J; Long Z; Guo G; Shi X; Wang C; Zang Y; Ding Z; Chen J; Zhang J; Dong L
Biomaterials; 2016 Jun; 90():72-84. PubMed ID: 26994345
[TBL] [Abstract][Full Text] [Related]
13. Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy.
Zang X; Zhang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Mol Pharm; 2019 Apr; 16(4):1714-1722. PubMed ID: 30860846
[TBL] [Abstract][Full Text] [Related]
14. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy.
Xu L; Xie X; Luo Y
Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy.
Zhang SY; Song XY; Li Y; Ye LL; Zhou Q; Yang WB
Pharmacol Res; 2020 Nov; 161():105111. PubMed ID: 33065284
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy.
Huang Z; Zhang Z; Jiang Y; Zhang D; Chen J; Dong L; Zhang J
J Control Release; 2012 Mar; 158(2):286-92. PubMed ID: 22119956
[TBL] [Abstract][Full Text] [Related]
18. Macrophage apoptosis using alendronate in targeted nanoarchaeosomes.
Jerez HE; Altube MJ; Gándola YB; González L; González MC; Morilla MJ; Romero EL
Eur J Pharm Biopharm; 2021 Mar; 160():42-54. PubMed ID: 33440242
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophages: role in cancer development and therapeutic implications.
Salmaninejad A; Valilou SF; Soltani A; Ahmadi S; Abarghan YJ; Rosengren RJ; Sahebkar A
Cell Oncol (Dordr); 2019 Oct; 42(5):591-608. PubMed ID: 31144271
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype.
Xu M; Liu M; Du X; Li S; Li H; Li X; Li Y; Wang Y; Qin Z; Fu YX; Wang S
J Immunol; 2015 May; 194(10):4997-5006. PubMed ID: 25876763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
